Long-term outcome of treat and extend intravitreal ziv-aflibercept therapy

• Published in: British journal of ophthalmology Vol. 103; no. 7; pp. 938 - 941
• Main Authors: Mansour, Ahmad M, Charbaji, Abdulrazzak, Farah, Michel Eid, Mansour, Hana A, Chhablani, Jay
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.07.2019
• Subjects: Adult; Age; Aged; Aged, 80 and over; Angiogenesis Inhibitors - administration & dosage; Diabetes; Edema; Female; Humans; Intravitreal Injections; Macular degeneration; Macular Degeneration - drug therapy; Macular Edema - drug therapy; Male; Middle Aged; Ophthalmology; Patients; Prospective Studies; Receptors, Vascular Endothelial Growth Factor - administration & dosage; Recombinant Fusion Proteins - administration & dosage; Retina; Vascular endothelial growth factor; New York; United States > US; Macula; Retina; Treatment other
• ISSN: 0007-1161; 1468-2079; 1468-2079
• DOI: 10.1136/bjophthalmol-2018-312593

AimTo assess the 30-month outcome of treat and extend (TAE) intravitreal ziv-aflibercept therapy in eyes with macular diseases.MethodsIn this prospective study, consecutive subjects received intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections for various macular diseases. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution) and central macular thickness (CMT) on spectral domain optical coherence tomography. Paired comparison was done using Wilcoxon signed-rank test calculator.ResultsFifty-three eyes of 48 subjects (33 naïve eyes) received intravitreal ziv-aflibercept and were followed between 12 and 30 months following TAE included neovascular age-related macular degeneration (nAMD) (35 eyes) and diabetic macular oedema (DMO) (18 eyes). In eyes with nAMD, CMT decreased by 107.8 µm at the 30-month follow-up (p=0.012) with BCVA gain of 0.52 (p=0.001). In eyes with DMO, CMT decreased by 224.3 µm at the 30-month follow-up (p=0.027) with BCVA gain of 0.46 (p=0.042). Combining all disease categories, the mean number of injections was 9.2 at month 12, 2.5 between 12 and 18 months, 1.6 between 18 and 24 months and 1.0 between 24 and 30 months.ConclusionsUsing TAE regimen, intravitreal ziv-aflibercept appeared efficacious at managing retinal disease through month 30 using the TAE regimen.